HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A

SSSE:600566
31.18
CNY
+0.30
(+0.97%)
1.97EPS
12.91P/E
23.62BMarket Cap
Apr 12Next Earn

Total Valuation

CNY

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A carries a market capitalization of 23.62B, placing it among publicly traded companies globally. Its enterprise value stands at 13.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap23.62B
Enterprise Value13.14B

Important Dates

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A's next confirmed earnings release is scheduled for April 12, 2027.

Earnings Date4/12/2027

Share Statistics

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A has 921.76M shares outstanding.

Shares Outstanding921.76M

Valuation Ratios

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A trades at a trailing price-to-earnings ratio of 12.91. The price-to-sales ratio is 3.96, and the price-to-book ratio stands at 1.68.

PE Ratio12.91
PS Ratio3.96
PB Ratio1.68
P/TBV Ratio1.75

Enterprise Valuation

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A trades at an EV/EBITDA multiple of 6.15 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.14B versus a market cap of 23.62B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.22
EV / EBITDA6.15
EV / EBIT6.15

Financial Position

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A maintains a current ratio of 4.88, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.97, indicating elevated leverage, while an interest coverage ratio of 115.25 demonstrates strong ability to service its debt obligations.

Current Ratio4.88
Quick Ratio4.22
Debt / Equity8.97
Debt / EBITDA0.59
Interest Coverage115.25

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A posted a return on equity (ROE) of 13.16, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.10 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.56, useful for judging operating efficiency across full business cycles. The company generates approximately 1.43M in revenue per employee across its workforce of 4,137.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.96 indicates how many times HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)13.16
Return on Assets (ROA)10.76
Return on Invested Capital (ROIC)12.10
Return on Capital Employed (ROCE)12.56
Revenue Per Employee1.43M
Employee Count4,137.00
Inventory Turnover2.96

Taxes

CNY

Over the twelve months ended September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A recorded 340.89M in income tax expense. That works out to an effective tax rate of 15.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.14B, leaving 1.82B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax340.89M
Effective Tax Rate15.93

Stock Price Statistics

CNY

As of the close on November 17, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A's stock has gained approximately 11.60% over the past 52 weeks. The 50-day moving average sits at 26.75, while the 200-day moving average is 26.52.

52-Week Price Change11.60%
50-Day Moving Average26.75
200-Day Moving Average26.52

Income Statement

CNY

Over the twelve months ended September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A generated 5.92B in revenue and converted that into 1.82B in net income, yielding earnings per share of 1.97. EBITDA reached 2.14B, while operating income came in at 1.90B.

Revenue5.92B
Gross Profit4.81B
Operating Income1.90B
Pretax Income2.14B
Net Income1.82B
EBITDA2.14B
EBIT2.14B
Earnings Per Share (EPS)1.97

Balance Sheet

CNY

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A holds 11.76B in cash and equivalents against 1.27B in total debt, resulting in a net debt position of -2.78B. Total book value stands at 14.10B, with working capital of 10.80B providing operational flexibility.

Cash & Cash Equivalents11.76B
Total Debt1.27B
Net Debt-2.78B
Equity (Book Value)14.10B
Book Value Per Share15.29
Working Capital10.80B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-259.73M

Margins

Over the twelve months ended September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A posted a gross margin of 81.25, reflecting its pricing power and cost economics. The operating margin of 31.99 and net profit margin of 30.66 provide insight into operational efficiency.

Gross Margin81.25
Operating Margin31.99
Pretax Margin36.13
Profit Margin30.66
EBITDA Margin36.09

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A paid dividends of 1.78 per share. The dividend payout ratio of 91.28 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A shareholders.

Dividend Per Share1.78
Payout Ratio91.28
Shareholder Yield2.49

Stock Splits

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A's most recent stock split took place on May 18, 2010 with a 10:13 split ratio.

Last Split Date5/18/2010
Split Ratio10:13

Scores

As of September 30, 2026, HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Class A has an Altman Z-Score of 7.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.07